Powered by

RDx BioScience Genetic Risk Testing Identifies Harmful Mutation in BRCA1 or BRCA2 Human Genes Indicating Higher Likelihood of Breast Cancer

Feb 05, 2019 - Business Wire

RDx BioScience (RDx) calls for increased use of genetic testing to identify mutations in BRCA1  and  BRCA2 , the genes discovered in the 1990s to be strongly associated with a high risk of breast cancer. RDX, a single source for care quality, risk evaluation and opioid expertise powered by a fast, full-service laboratory, raises awareness that these gene mutations are heritable, can be passed from parent to child, and 70 percent of women with mutations in BRCA1 or BRCA2 will develop breast can...